AZD6738-d4

1352226-88-0(unlabelled)

CS-T-103295

C₂₀H₂₀D₄N₆O₂S

416.53

C[C@@H]1COCCN1C2=NC(C3=C4C=CNC4=NC=C3)=NC(C5([S@@](=N)(C)=O)C([2H])([2H])C5([2H])[2H])=C2

Stable Isotopes

-

Refer MSDS for complete information.

4-[4-[1-[[S(R)]-S-Methylsulfonimidoyl]cyclopropyl]-6-[(3R)-3-methyl-4-morpholinyl]-2-pyrimidinyl]-1H-pyrrolo[2,3-b]pyridine-d4; AZD 6738-d4

Karnitz, Larry M., et al.: Clin Cancer Res., 21, 4780 (2015); Kwok, Marwan., et al.: Blood., 127, 582 (2016)

4-[4-[1-[[S(R)]-S-Methylsulfonimidoyl]cyclopropyl]-6-[(3R)-3-methyl-4-morpholinyl]-2-pyrimidinyl]-1H-pyrrolo[2,3-b]pyridine-d4; AZD 6738-d4

AZD6738-d4, is a labeled analogue of AZD6738 (A965423), an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor AZD6738 selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In addition, AZD6738 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it i

Refer MSDS for complete information.